Pfizer, Inc. (NYSE:PFE) Shares Bought by Alpha Windward LLC
Alpha Windward LLC increased its position in Pfizer, Inc. (NYSE:PFE) by 8.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,127 shares of the biopharmaceutical company’s stock after buying an additional 740 shares during the period. Alpha Windward LLC’s holdings in Pfizer were worth $307,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of PFE. Asset Planning Services Ltd. raised its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer during the first quarter valued at approximately $121,000. Finally, Cascade Investment Advisors Inc. increased its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares during the period. 69.95% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer, Inc. (NYSE PFE) traded up 0.63% during mid-day trading on Friday, reaching $33.64. The company had a trading volume of 25,790,667 shares. The company has a market cap of $200.76 billion, a price-to-earnings ratio of 24.61 and a beta of 1.00. The firm’s 50-day moving average price is $33.38 and its 200 day moving average price is $33.25. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.95.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. Equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.80%. Pfizer’s dividend payout ratio is presently 94.12%.
PFE has been the topic of several analyst reports. Citigroup Inc. downgraded Pfizer from a “neutral” rating to a “sell” rating and lowered their price target for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. Barclays PLC reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Sanford C. Bernstein reiterated a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price target on shares of Pfizer in a report on Thursday, April 27th. Finally, Morgan Stanley restated a “neutral” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $37.77.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.